Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs MaxLinear Inc. Common Stock (MXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs MaxLinear Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while MaxLinear Inc. Common Stock trades at $76.01 (market cap $8.04B). The key difference: Kymera Therapeutics Inc. Common Stock and MaxLinear Inc. Common Stock are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, MaxLinear Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and MaxLinear Inc. Common Stock for 3 Days on average.
| KYMR | MXL | |
|---|---|---|
Market Cap | $8.87B | $8.04B |
Volume | 779,107 | 2,554,408 |
Sector | Health | Technology |
52-Week High | $127.31 | $128.03 |
52-Week Low | $55.80 | $13.05 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.26B | $8.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MaxLinear (MXL) trades at $88.64, down 0.39% on the day, with strong technical momentum indicated by bullish moving averages and key support at $87. The company shows impressive revenue growth with Q2 2026 EPS beating expectations at $0.35 versus $0.33, though profitability remains challenged with a -18.24% net income margin. Recent AI-focused product launches like Topaz™ PON chips and strong infrastructure demand position MXL for continued growth.
MXL presents a compelling growth story driven by AI infrastructure demand, with analyst consensus at Buy (64.7%) and $91.67 price target offering 3.4% upside. However, negative profitability metrics and cash flow concerns require careful monitoring. The stock's 50.7% September surge (Motley Fool, Oct 2) reflects optimism, but execution risks and valuation premium warrant cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About MaxLinear Inc. Common Stock
MaxLinear develops analog and mixed-signal semiconductors for connectivity, communications, industrial, and data center applications.
Read more on MXL →
